Cargando…

Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[(18)F]-fluoroethyl)-l-tyrosine PET

PURPOSE: Integrated histomolecular diagnostics of gliomas according to the World Health Organization (WHO) classification of 2016 has refined diagnostic accuracy and prediction of prognosis. This study aimed at exploring the prognostic value of dynamic O-(2-[(18)F]-fluoroethyl)-l-tyrosine (FET) PET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauer, Elena K., Stoffels, Gabriele, Blau, Tobias, Reifenberger, Guido, Felsberg, Jörg, Werner, Jan M., Lohmann, Philipp, Rosen, Jurij, Ceccon, Garry, Tscherpel, Caroline, Rapp, Marion, Sabel, Michael, Filss, Christian P., Shah, Nadim J., Neumaier, Bernd, Fink, Gereon R., Langen, Karl-Josef, Galldiks, Norbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188701/ https://www.ncbi.nlm.nih.gov/pubmed/32034446 http://dx.doi.org/10.1007/s00259-020-04695-0

Ejemplares similares

Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement
por: Rosen, Jurij, et al.
Publicado: (2021)

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
por: Wollring, Michael M., et al.
Publicado: (2022)

Two Decades of Brain Tumour Imaging with O-(2-[(18)F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience
por: Heinzel, Alexander, et al.
Publicado: (2022)

Predicting IDH genotype in gliomas using FET PET radiomics
por: Lohmann, Philipp, et al.
Publicado: (2018)

MLTI-17. DIFFERENTIATION OF RADIATION INJURY FROM RECURRENT BRAIN METASTASIS USING COMBINED FET PET/MRI RADIOMICS
por: Lohmann, Philipp, et al.
Publicado: (2019)

Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure
por: Galldiks, Norbert, et al.
Publicado: (2012)

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
por: Mareike, Müller, et al.
Publicado: (2021)

O-(2-[(18)F]fluoroethyl)-l-tyrosine PET in gliomas: influence of data processing in different centres
por: Filss, Christian P., et al.
Publicado: (2017)

Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis
por: Lohmann, Philipp, et al.
Publicado: (2018)

Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation
por: Ceccon, Garry, et al.
Publicado: (2018)

Role of the default mode resting-state network for cognitive functioning in malignant glioma patients following multimodal treatment
por: Kocher, Martin, et al.
Publicado: (2020)

Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide
por: Berger, Kerstin, et al.
Publicado: (2020)

Investigation of Cerebral O-(2-[(18)F]Fluoroethyl)-L-Tyrosine Uptake in Rat Epilepsy Models
por: Stegmayr, Carina, et al.
Publicado: (2020)

Case Report: Disruption of Resting-State Networks and Cognitive Deficits After Whole Brain Irradiation for Singular Brain Metastasis
por: Kocher, Martin, et al.
Publicado: (2021)

Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI
por: Galldiks, Norbert, et al.
Publicado: (2019)

A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma
por: Kebir, Sied, et al.
Publicado: (2020)

FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation
por: Lohmann, Philipp, et al.
Publicado: (2020)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

Lesion-Function Analysis from Multimodal Imaging and Normative Brain Atlases for Prediction of Cognitive Deficits in Glioma Patients
por: Kocher, Martin, et al.
Publicado: (2021)

Alterations in white matter fiber density associated with structural MRI and metabolic PET lesions following multimodal therapy in glioma patients
por: Friedrich, Michel, et al.
Publicado: (2022)

The impact of brain lesions on health-related quality of life in patients with WHO CNS grade 3 or 4 glioma: a lesion-function and resting-state fMRI analysis
por: Heinzel, Alexander, et al.
Publicado: (2023)

Extracranial Metastases of a Cerebral Glioblastoma: A Case Report and Review of the Literature
por: Rosen, Jurij, et al.
Publicado: (2018)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas
por: Werner, Jan-Michael, et al.
Publicado: (2022)

Evaluation of factors influencing (18)F-FET uptake in the brain
por: Verger, Antoine, et al.
Publicado: (2017)

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
por: Ceccon, Garry, et al.
Publicado: (2020)

Amino acid PET and MR perfusion imaging in brain tumours
por: Filss, Christian P., et al.
Publicado: (2017)

Combined (18)F-FET PET and diffusion kurtosis MRI in posttreatment glioblastoma: differentiation of true progression from treatment-related changes
por: D’Amore, Francesco, et al.
Publicado: (2021)

Adapting MR-BrainPET scans for comparison with conventional PET: experiences with dynamic FET-PET in brain tumours
por: Lohmann, Philipp, et al.
Publicado: (2014)

Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors
por: Werner, Jan-Michael, et al.
Publicado: (2020)

Evaluation of FET PET Radiomics Feature Repeatability in Glioma Patients
por: Gutsche, Robin, et al.
Publicado: (2021)

Methylation class oligosarcoma may encompass IDH-wildtype gliomas
por: Ebrahimi, Azadeh, et al.
Publicado: (2022)

PDPN contributes to constructing immunosuppressive microenvironment in IDH wildtype glioma
por: Wang, Xuya, et al.
Publicado: (2022)

Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
por: Liu, Elisa K, et al.
Publicado: (2022)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma
por: Saaid, Ayoub, et al.
Publicado: (2022)

GEN-13 FIREWORK PATTERN OF CANCER GENESIS FOR GLIOBLASTOMA, IDH-WILDTYPE
por: Yoon, Seon-Jin, et al.
Publicado: (2019)

Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses
por: Liu, Yu-Qing, et al.
Publicado: (2019)

Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives
por: Langen, Karl-Josef, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cngg66eqdoq9b7pev2ge3k1qqg